A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
A phase 2 trial of Ciltacabtagene autoleucel, Talquetamab in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.
Overview
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma is a phase 2 interventional study registered as NCT06550895 by Janssen Research & Development, LLC, with 11 participants enrolled, started 2024-09-16 and due to reach its primary completion in 2027-08-26. Interventions recorded: Cilta-cel, Talquetamab. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Shares Talquetamab, Johnson & Johnson, Multiple myeloma.
- TrialA Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Shares Talquetamab, Johnson & Johnson, Multiple myeloma.
- TrialA Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind
Shares Talquetamab, Ciltacabtagene autoleucel, Johnson & Johnson, Multiple myeloma.
- TrialA Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Shares Ciltacabtagene autoleucel, Johnson & Johnson, Multiple myeloma.
- TrialA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi
Shares Talquetamab, Johnson & Johnson, Multiple myeloma.
- TrialA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal
Shares Talquetamab, Johnson & Johnson, Multiple myeloma.
- TrialA Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul
Shares Ciltacabtagene autoleucel, Johnson & Johnson, Multiple myeloma.
- TrialA Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez
Shares Talquetamab, Johnson & Johnson, Multiple myeloma.